Physician profile
James D Pharaoh
NPI 1578535043
$20,328.75
in general payments reported to CMS, 2019-2025
49 companies · $3,481 in 2025
The $3,481 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,559 · 2020: $1,818 · 2021: $2,613 · 2022: $2,590 · 2023: $3,595 · 2024: $3,673 · 2025: $3,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,641.49 |
| Education | $107.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,647.83 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $2,877.90 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,519.11 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Insmed, INC. | $1,375.73 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $1,337.43 | 2019-2025 | Tyvaso, Tyvaso, Orenitram |
| Amgen INC. | $919.89 | 2021-2025 | Tezspire |
| Electromed, INC. | $861.66 | 2019-2025 | Smartvest |
| Genzyme Corporation | $785.58 | 2021-2025 | |
| Grifols USA, LLC | $730.06 | 2019-2025 | Prolastin-C Liquid |
| Genentech USA, INC. | $681.44 | 2019-2023 | Xolair |
| Actelion Pharmaceuticals US, INC. | $571.69 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $365.23 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $341.84 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $276.75 | 2020-2025 | Winrevair, Zerbaxa, Capvaxive |
| Baxter Healthcare | $236.62 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imvaria INC. | $236.52 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $211.96 | 2022-2024 | Glassia |
| Pulmonx Corporation | $197.26 | 2022-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Sunovion Pharmaceuticals INC. | $175.53 | 2019-2021 | |
| Allergan, INC. | $175.04 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $157.12 | 2019 | |
| Advanced Respiratory, INC | $125.01 | 2019-2021 | |
| Philips North America LLC | $122.08 | 2019-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Csl Behring | $110.77 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $110.71 | 2021-2025 | Acthar |
| Ucb, INC. | $99.98 | 2023 | Briviact |
| Mallinckrodt Enterprises LLC | $92.29 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $82.76 | 2019 | |
| Ani Pharmaceuticals, INC. | $81.14 | 2024 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Gilead Sciences, INC. | $70.33 | 2021-2022 | |
| Shionogi INC | $69.80 | 2021-2024 | Fetroja |
| Inogen, INC. | $69.52 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Verona Pharma, INC. | $60.28 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $56.21 | 2019-2021 | |
| Cmp Pharma, INC. | $47.46 | 2023 | Norliqva, Tadliq |
| Circassia INC. | $45.67 | 2019-2020 | |
| Viatris Specialty LLC | $43.32 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $40.65 | 2020 | |
| Mayne Pharma Commercial LLC | $39.77 | 2021 | |
| La Jolla Pharmaceutical Company | $39.53 | 2024 | Giapreza |
| Pfizer INC. | $28.69 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.06 | 2021 | |
| Vifor Pharma, INC. | $21.99 | 2024 | Zemaira |
| Portola Pharmaceuticals, LLC | $19.12 | 2019 | |
| Phadia US INC. | $17.75 | 2024 | Immunocap |
| Abbvie INC. | $16.97 | 2023 | |
| Nabriva Therapeutics, Plc | $16.94 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $16.77 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Pharaoh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.